Clinical Trial Details

Trial ID: L0198
Source ID: NCT03987074
Associated Drug: Semaglutide
Title: Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)
Acronym: --
Status: Completed
Study Results: Has Results
Results: https://ClinicalTrials.gov/show/NCT03987074/results
Conditions: Nonalcoholic Steatohepatitis
Interventions: Drug: Semaglutide|Drug: Firsocostat|Drug: Cilofexor
Outcome Measures: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)|Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities
Sponsor/Collaborators: Gilead Sciences|Novo Nordisk A/S
Gender: All
Age: 18 Years to 75 Years ?? (Adult, Older Adult)
Phases: Phase 2
Enrollment: 109
Study Type: Interventional
Study Designs: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
Start Date: July 29, 2019
Completion Date: July 13, 2020
Results First Posted: July 15, 2021
Last Update Posted: July 15, 2021
Locations: Institute for Liver Health - Arizona Liver Health, Chandler, Arizona, United States|Southern California Research Centers, Coronado, California, United States|University of California San Diego (UCSD), La Jolla, California, United States|Ruane Clinical Research Group, Inc, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Inland Empire Clinical Trials, LLC, Rialto, California, United States|Medical Associates Research Group, San Diego, California, United States|Gastrointestinal Specialists of Georgia, Marietta, Georgia, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Jubilee Clinical Research, Inc., Las Vegas, Nevada, United States|Northwell Health, Manhasset, New York, United States|Gastro One, Huntersville, North Carolina, United States|University Gastroenterology, Providence, Rhode Island, United States|Gastro One, Germantown, Tennessee, United States|Quality Medical Research, PLLC, Nashville, Tennessee, United States|Texas Clinical Research Institute, Arlington, Texas, United States|The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States|American Research Corporation, San Antonio, Texas, United States
URL: https://ClinicalTrials.gov/show/NCT03987074

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D327 Semaglutide Chemical drug DB13928 GLP1R agonist Antidiabetic drug Under clinical trials Details
D078 Cilofexor Chemical drug DB15168 FXR agonist Enhance lipid metabolism Under clinical trials Details
D136 Firsocostat Chemical drug DB16166 ACC inhibitor Enhance lipid metabolism Under clinical trials Details